THE ROLE OF INTERLEUKIN 2 IN HUMAN IMMUNODEFICIENCY STATES

Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

THE ROLE OF INTERLEUKIN 2 IN HUMAN IMMUNODEFICIENCY STATES

Cellular and Molecular Biology of Lymphokines. Sorg C, Schimpl A, eds. New York, Academic Press Inc., p. 755-9, 1985.. Unique Identifier : AIDSLINE ICDB/87632377
Welte K; Kolitz JE; Merluzzi VJ; Flomenberg N; Engert A; Miller GA; Holloway K; Sykora KW; Venuta S; O'Reilly RJ; et al; Lab. of Developmental Hematopoiesis, Memorial Sloan-Kettering; Cancer Center, New York, NY 10021

Abstract: Results obtained to date on endogenous lymphocyte interleukin 2 (IL2) production and proliferation in the presence or absence of exogenous IL2 in patients (pts) with primary and acquired immunodeficiency are reported, as are preliminary results of Phase I clinical trials. OKT3 stimulation in vitro of peripheral blood mononuclear cells of 100 pts with various immunodeficiencies permitted identification of three pt subgroups: (1) minor to no response to exogenous IL2, (2) partial restoration of proliferative response by IL2, and (3) normalization of proliferative response by IL2. Abnormal responses of peripheral blood T cells to OKT3 antibody were correlated with defective IL2 production in all cases. Fifteen pts with acquired immunodeficiency syndrome (AIDS), lymphoma and immunodeficiency, or severe combined immunodeficiency were treated with highly purified IL2 (max daily dose 40,000 U/m2, max total dose 855,000 U/m2, as continuous infusion or daily bolus). An increase in platelet count was seen in one AIDS pt, a decrease in the serum level of monoclonal Ig was seen in another, and a minor tumor response was seen in a pt with diffuse histiocytic lymphoma. Recombinant IL2 (to a maximally tolerated daily dose of 2 x 10(6) U/m2) was given to 24 pts, including those with Kaposi's sarcoma and RAEB. Of 19 pts evaluable for response, 8 had disease progression and 10 had stable disease. (10 Refs)

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Bone Marrow/TRANSPLANTATION Bone Marrow Transplantation Drug Evaluation Human Immunologic Deficiency Syndromes/IMMUNOLOGY/*THERAPY Interleukin-2/BIOSYNTHESIS/*THERAPEUTIC USE Lymphoma/IMMUNOLOGY/*THERAPY Recombinant Proteins/*THERAPEUTIC USE MEETING PAPER

870530
M8750356

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .